CBPE Capital

The UK-focused fund, which had excess demand before the Brexit vote, includes a GP commitment of 2%.

The UK mid-market firm is defying Brexit uncertainty as it hurtles toward its £425m target.

The fund, which officially launched last May, is expected to reach its £425m target by the summer.

AIM-listed pharma company Clinigen Group will pay £225m for the unlicensed medicines importer and supplier

LDC will invest £18.5m to support Away Resorts’ management team in its growth plan

Former Aurum Holdings CEO Justin Stead will join the retailer’s board as chairman

The sale generated a 2.4x return for CBPE's Fund VIII

The UK mid-market firm has sold Rosemont Pharmaceuticals to a US trade buyer for £180m – having more than doubled EBITDA during its period of ownership.

The pros and cons of in-house versus outsourced capital raising was debated at PEI’s Investor Relations forum this week.

Who are the young guns showing innovation in the industry? Who has the X factor that marks them as a future leader? Our Future 40 list of the 40 individuals aged under 40 set to shape private equity over the next decade.

The US corporate pension will reduce its 80 GPs over time but plans to increase its overall exposure to private equity.

Just two foreign fund managers make the top 10 ranking of UK-focused firms.

The firm has amassed more than €500m for its latest vehicle, which has a hard-cap of €750m.

The investment funds a bolt-on acquisition for MDNX from LDC, with Equistone becoming the majority owner in the newly-formed group.

The Bahrain-headquartered alternatives group has sold Moody International to a trade buyer for $450m.

The London-based law firm has promoted partner Richard Moulton to lead its private equity practice as former head Mark Spinner takes over the firm's corporate practice.